Phase 3 results posted: A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread — Bristol-Myers Squibb
Why now
Thesis: Phase 3 registry update for subcutaneous nivolumab
Catalyst to watch: Disclosure of efficacy direction or regulatory filing
Main risk: No efficacy direction disclosed in text
Why it matters
Phase 3 results posting for subcutaneous nivolumab is a registry update; no efficacy direction disclosed in the text.
Details
Sponsor: Bristol-Myers Squibb; Status: Active Not Recruiting; Conditions: Clear Cell Renal Cell Carcinoma; Interventions: Nivolumab and rHuPH20, Nivolumab; Enrollment: 681 (actual); First posted: 2021-03-22; Results posted: 2026-09-22; NCT: NCT04810078
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-22 12:00 UTC